Mirum Pharmaceuticals, Inc.
As of Oct 22, 2026, Mirum Pharmaceuticals is in Stage 4, the downtrend phase, now in week 3 (since Oct 2, 2026). It closed at $83.10, 35.4% below its 52-week high and below its 200-day average, which is rising.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is MIRM early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
MIRM among Biotechnology139th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …139 | MIRM | Stage 4 · wk 3 | 70 | −7.0% |
Mirum Pharmaceuticals: quick answers
What stage is Mirum Pharmaceuticals in?
As of Oct 22, 2026, Mirum Pharmaceuticals (MIRM) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 2, 2026 and is in week 3. What the four stages mean
Is Mirum Pharmaceuticals in an uptrend?
No. Mirum Pharmaceuticals is in a Stage 4 downtrend. It trades 15.8% below its 200-day average, which is rising.
How far is Mirum Pharmaceuticals from its 52-week high?
Mirum Pharmaceuticals closed at $83.10 on Oct 22, 2026, 35.4% below its 52-week high of $128.57. Its 52-week low is $64.10.
How has Mirum Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Mirum Pharmaceuticals is up 20.5% over the past year and up 6.4% so far in 2026.
Which sector and industry is Mirum Pharmaceuticals in?
Mirum Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.